Market Place
Sourcing Support
Candel Therapeutics Reports Q3 2024 Results & Highlights
14 Nov 2024 //
GLOBENEWSWIRE
C&el Therapeutics to Present at Jefferies London Healthcare Conf
07 Nov 2024 //
GLOBENEWSWIRE
C&el Therapeutics Presents Preclinical Data at SITC Annual Meeting
05 Nov 2024 //
GLOBENEWSWIRE
Candel Showcases Cancer Therapy Candidates at IOVC 2024
28 Oct 2024 //
#N/A
Candel To Present CAN-3110 Data In Melanoma At SITC 2024
04 Oct 2024 //
GLOBENEWSWIRE
Kineta Announces KVA12123 Poster At SITC 2024
04 Oct 2024 //
GLOBENEWSWIRE
Candel Therapeutics to Present at H.C. Wainwright Global Investment Conference
03 Sep 2024 //
GLOBENEWSWIRE
Candel Therapeutics Reports Q2 2024 Results And Corporate Highlights
13 Aug 2024 //
GLOBENEWSWIRE
Candel To Participate In H.C. Wainwright Immune Cell Engager Conference
18 Jun 2024 //
GLOBENEWSWIRE
Candel Therapeutics to Join Russell 3000® Index
11 Jun 2024 //
GLOBENEWSWIRE
Candel`s CAN-2409 Positive Phase 2 Data In Borderline Resectable Pancreatic
03 Jun 2024 //
ACCESSWIRE
FDA Grants Orphan Status To CAN-3110 For Recurrent High-Grade Glioma
30 May 2024 //
GLOBENEWSWIRE
Candel Can-2409 Os Results: Phase 2 Nsclc Ici Nonresponsive Asco24
23 May 2024 //
GLOBENEWSWIRE
Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
22 May 2024 //
GLOBENEWSWIRE
Candel To Host NSCLC R&D Panel At ASCO 2024
20 May 2024 //
GLOBENEWSWIRE
Candel Therapeutics Reports Q1 2024 Results, Corporate Highlights
14 May 2024 //
GLOBENEWSWIRE
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb
09 May 2024 //
PR NEWSWIRE
Candel to Present at ASCO 2024 Annual Meeting
25 Apr 2024 //
GLOBENEWSWIRE
Candel Gets FDA Orphan Drug Status For Pancreatic Cancer Treatment
11 Apr 2024 //
GLOBENEWSWIRE
Candel Presents AACR Data on Solid Tumor Immunotherapy
09 Apr 2024 //
GLOBENEWSWIRE
Candel Announces Positive Data from Ph 2 Trial of CAN-2409 in Pancreatic Cancer
04 Apr 2024 //
GLOBENEWSWIRE
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
28 Mar 2024 //
GLOBENEWSWIRE
Candel Announces Oral Presentation Update on Phase 1b Clinical Trial of CAN-3110
28 Mar 2024 //
GLOBENEWSWIRE
Candel Therapeutics Announces an Upcoming Presentation at the AACR
05 Mar 2024 //
GLOBENEWSWIRE
CAN-3110 Receives FDA Fast Track Designation
13 Feb 2024 //
GLOBENEWSWIRE
Candel Therapeutics Sets Path to Success
05 Feb 2024 //
GLOBENEWSWIRE
Candel Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer
12 Dec 2023 //
GLOBENEWSWIRE
Candel Announces Restructuring to Prioritize Resources on Key Value Drivers
28 Nov 2023 //
GLOBENEWSWIRE
Candel’s flame dims as layoffs hit 50% of the team
28 Nov 2023 //
FIERCE BIOTECH
Candel Therapeutics Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Candel Therapeutics Presents Preclinical Data from enLIGHTEN Discovery Platform
04 Nov 2023 //
GLOBENEWSWIRE
Candel Therapeutics Announces Positive Interim Data from Phase 2 of CAN-2409
03 Nov 2023 //
GLOBENEWSWIRE
Candel Announces Nature Publication Showing Extended Survival with CAN-3110
18 Oct 2023 //
GLOBENEWSWIRE
Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations
27 Sep 2023 //
GLOBENEWSWIRE
Candel Reports Initial Survival Data from Phase 2 Clinical Trial of CAN-2409
26 Sep 2023 //
GLOBENEWSWIRE
Candel to Participate in the H.C. Wainwright 25th Annual Global Conference
06 Sep 2023 //
GLOBENEWSWIRE
Candel Therapeutics Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Candel to Participate in the Canaccord Genuity 43rd Annual Growth Conference
02 Aug 2023 //
GLOBENEWSWIRE
Candel Announces It Expects to Report Data from Phase 2 Trial of CAN-2409
13 Jun 2023 //
GLOBENEWSWIRE
Candel Appoints Nicoletta Loggia, PhD, RPh to its Board of Directors
08 Jun 2023 //
GLOBENEWSWIRE
Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
05 Jun 2023 //
GLOBENEWSWIRE
Candel Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110
19 May 2023 //
GLOBENEWSWIRE
Candel Therapeutics Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO
02 May 2023 //
GLOBENEWSWIRE
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409
17 Apr 2023 //
GLOBENEWSWIRE
Candel Reports 4Q and Full Reports Full 2022 FYR and Recent Corporate Highlights
30 Mar 2023 //
GLOBENEWSWIRE
Candel to Participate in Guggenheim Healthcare Talks 2023 Oncology Day
01 Feb 2023 //
GLOBENEWSWIRE
Candel Therapeutics to Participate in Upcoming B. Riley Oncology Conference
12 Jan 2023 //
GLOBENEWSWIRE
Candel Therapeutics R&D Day Presentations Spotlight its Advanced Pipeline
06 Dec 2022 //
GLOBENEWSWIRE
Candel Therapeutics to Host Virtual R&D Day on December 6, 2022
29 Nov 2022 //
GLOBENEWSWIRE
Candel Announces Oral Presentation of Data from its Ph1 Trial of CAN-3110
18 Nov 2022 //
GLOBENEWSWIRE
Candel Announces Late-Breaking Oral Presentation at SITC ical Trial in Patients
11 Nov 2022 //
GLOBENEWSWIRE
Candel Therapeutics Announces Upcoming Clinical Data Presentations at SITC
07 Nov 2022 //
GLOBENEWSWIRE
Candel Therapeutics Upcoming Investor Conference Participation for November
01 Nov 2022 //
GLOBENEWSWIRE
Candel and the University of Pennsylvania to assess solid tumour therapies
28 Oct 2022 //
PHARMACEUTICAL-TECHNOLOGY
Candel Partners with University of Pennsylvania’s Center for Immunotherapies
26 Oct 2022 //
GLOBENEWSWIRE
Candel Therapeutics Receives Orphan Drug Designation from the EMAfor CAN-2409
15 Sep 2022 //
GLOBENEWSWIRE
Candel Therapeutics Announces Two Executive Leadership Appointments
07 Sep 2022 //
GLOBENEWSWIRE
Candel Therapeutics Upcoming Investor Conference Participation
06 Sep 2022 //
GLOBENEWSWIRE
Candel Therapeutics Reports Second Quarter 2022 Financial Results
05 Aug 2022 //
GLOBENEWSWIRE
